New partnership provides South Africa with vaccines
The exclusive agreement guarantees affordable and accessible vaccine to people living in South Africa and also provides the South African government a dependable supply of medical products.
“This agreement will enable Cipla Medpro to become a significant player in the market,” Paul Miller, CEO of Cipla Medpro, South Africa, said. “With a presence in 140 countries and 1.3 billion doses manufactured and sold, SII is an ideal ally for Cipla Medpro, and this partnership will be instrumental in addressing the national vaccine shortage.”
This partnership will help people living throughout South Africa.
“We are confident that this agreement will support the Department of Health in rolling out its expanded immunization program,” Miller said. “Cipla Medpro will continuously look to partner with organizations that are aligned with the company’s ethos of advancing healthcare for all.”
SII develops a wide range of vaccines, including Hepatitis B, Polio, Tetanus, Diphtheria, BCG (Tuberculosis), Mumps, Measles and Rubella. Now, South Africa will be a member in many of these portfolios.